outcomes of a community-based bamlanivimab infusion program for covid-19

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

E Michelson; S Crawford; S Monks

Mar 23, 2023